Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: FDA OKs IntelligentMDx C. Difficile Abbott m2000 Assay

Premium

IntelligentMDx said today that it has received US Food and Drug Administration clearance for its IMDx C. difficile for Abbott m2000 assay, a test that detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile in human stool specimens.

IMDx's analytical reactivity studies have demonstrated that its C. difficile assay is capable of detecting 31 different strains representing the global diversity of C. difficile, including NAP1 and tcdB variants.

C. difficile is the leading cause of hospital-acquired diarrhea and is linked to approximately 14,000 deaths in the United States annually, the company said.

IMDx's C. difficile assay is the company's third to receive FDA clearance in the last three months for use on Abbott's fully-automated m2000 system— following the IMDx VanR for Abbott m2000 and IMDx Flu A/B and RSV for Abbott m2000 assays (PCR 9/12/2013)

IMDx has a multi-year distribution agreement with Abbott encompassing a broad real-time PCR test menu designed, developed and manufactured for use on the m2000 system (PCR 3/17/2011).

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.